Analysed SAVARA INC (SVRA:NASDAQ) News Sources
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
15-04-2026
yahoo.com
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
14-04-2026
yahoo.com
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
07-04-2026
yahoo.com
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
30-03-2026
yahoo.com
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
13-03-2026
yahoo.com
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
06-03-2026
yahoo.com
What is the current price of SAVARA INC (SVRA:NASDAQ)?
The current price of SAVARA INC (SVRA:NASDAQ) is $5.28.
SAVARA INC (SVRA:NASDAQ) absolute price change since previous trading day?
The absolute price change of SAVARA INC (SVRA:NASDAQ) since the previous trading day is $-0.33.
SAVARA INC (SVRA:NASDAQ) percentage price change since previous trading day?
The percentage price change of SAVARA INC (SVRA:NASDAQ) since the previous trading day is -5.8824%.
What is the most recent average sentiment score for SAVARA INC (SVRA:NASDAQ)?
The most recent average sentiment score for SAVARA INC (SVRA:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for SAVARA INC (SVRA:NASDAQ)?
The most recent sentiment for SAVARA INC (SVRA:NASDAQ) is .
SEC-8K** Filing Available For SAVARA INC (SVRA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.